Salman Punekar, MD
Medical Oncology · New York, NYNPI 1730454034
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (55.9%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. 7 manufacturers reported payments, led by Regeneron Healthcare Solutions, Inc. at 58.9% of the total. 2025 is the largest year on record at $4,826, 5.9 times the $814 reported in 2021. That places this record below the midpoint for medical oncology clinicians in NY, where the typical reported total is $4,912.
Across 20 payments — averaging $297.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron Healthcare Solutions, Inc.$4K
- Deciphera Pharmaceuticals Inc.$1K
- Catalyst Pharmaceuticals, Inc.$600
- Genentech USA, Inc.$287
- Tempus AI, Inc$198
- AstraZeneca$171
- plus $89 from 1 others
Across 205 payments — averaging $28,679 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$4.8M
- AstraZeneca$339K
- Merck$321K
- Iovance Biotherapeutics, Inc.$162K
- Daiichi Sankyo Inc.$142K
- Biontech SE$69K
- plus $3K from 1 others
What the payments were for
- Consulting fees$3,32456%
- Speaking & faculty fees$1,70029%
- Food & beverage$92616%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. | 4 | $3,504 |
| Deciphera Pharmaceuticals Inc. | 1 | $1,100 |
| Catalyst Pharmaceuticals, Inc. | 1 | $600 |
| Genentech USA, Inc. | 2 | $287 |
| Tempus AI, Inc | 9 | $198 |
| AstraZeneca | 2 | $171 |
| Clinigen, Inc. | 1 | $89 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LIBTAYO$3,450
- VIMSELTINIB$1,100
- FIRDAPSE$600
- TAGRISSO$125
How this compares
$5,950 in reported general payments places this provider in the 50th percentile of 498 medical oncology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Doxycycline Hyclate | 12 | $289 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in New York
- Craig ThompsonNew York$4.8M
- Andrew SeidmanNew York$1.3M
- Joshua RichterNew York$971K
- Edward GelmannNew York$944K
- Ghassan Abou-AlfaNew York$825K
- Miguel PeralesNew York$769K
- Komal JhaveriNew York$642K
- Joshua BrodyNew York$492K
- Aiwu HeNew York$445K
- Raajit RampalNew York$418K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.